The Effect of Postoperative Use of Teriparatide Reducing Screw Loosening in Osteoporotic Patients.

Kim JW, Park SW, Kim YB, Ko MJ

Journal of Korean Neurosurgical Society4 May 2018Cited by 46 (Europe PMC)

PMID29724093PMCIDPMC6046574DOI10.3340/jkns.2017.0216PepBankPUB-29724093

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
After lumbar fusion in osteoporosis, screw loosening within 6 months did not differ significantly between teriparatide and risedronate.
In plain wordsAfter spine surgery, screw loosening within 6 months did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeScrew loosening within 6 months
Study
n = 84
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Screw loosening
6.9%
teriparatide within 6 months
Screw loosening
6.8%
BP within 6 months
Source sentences
Summary
The number of PS loosening within 6 months after surgery did not show a significant difference between the teriparatide group (6.9%, 12/172) and the BP group (6.8%, 18/272).
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this retrospective study was to examine the efficacy of teriparatide treatment started immediately after lumbar spinal surgery to prevent pedicle screw loosening in patients with osteoporosis.
Summary · context
We included 84 patients with osteoporosis and degenerative lumbar disease who underwent transforaminal interbody fusion and PS fixation and received parathyroid hormone or bisphosphonate (BP) postoperatively.
Summary · context
They were divided into teriparatide group (daily injection of 20 μg of teriparatide for 6 months, 33 patients, 172 screws) and BP group (weekly oral administration of 35 mg of risedronate, 51 patients, 262 screws).
Summary · context
Both groups received calcium (500 mg/day) and cholecalciferol (1000 IU/day) together.
Report a problemFND-2972409301
02HumanObservational studyEfficacy outcome
After lumbar fusion in osteoporosis, teriparatide was linked to less screw loosening during months 6-12 than risedronate.
In plain wordsAfter spine surgery, teriparatide was linked to less screw loosening during months 6-12 than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseScrew loosening during months 6-12
Study
n = 84
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Screw loosening
2.3%
teriparatide months 6-12
Screw loosening
9.2%
BP months 6-12
Source sentences
Summary
However, during 6-12 months after surgery, it was significantly lower in the teriparatide group (2.3%, 4/172) than the BP group (9.2%, 24/272) (p<0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this retrospective study was to examine the efficacy of teriparatide treatment started immediately after lumbar spinal surgery to prevent pedicle screw loosening in patients with osteoporosis.
Summary · context
We included 84 patients with osteoporosis and degenerative lumbar disease who underwent transforaminal interbody fusion and PS fixation and received parathyroid hormone or bisphosphonate (BP) postoperatively.
Summary · context
They were divided into teriparatide group (daily injection of 20 μg of teriparatide for 6 months, 33 patients, 172 screws) and BP group (weekly oral administration of 35 mg of risedronate, 51 patients, 262 screws).
Summary · context
Both groups received calcium (500 mg/day) and cholecalciferol (1000 IU/day) together.
Report a problemFND-2972409302
03HumanObservational studyEfficacy outcome
After lumbar fusion in osteoporosis, the number of patients with screw loosening did not differ significantly between teriparatide and risedronate.
In plain wordsAfter spine surgery, the number of patients with loose screws did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePatients with screw loosening
Study
n = 84
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference in the number of patients showing PS loosening between the teriparatide and BP groups.
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this retrospective study was to examine the efficacy of teriparatide treatment started immediately after lumbar spinal surgery to prevent pedicle screw loosening in patients with osteoporosis.
Summary · context
We included 84 patients with osteoporosis and degenerative lumbar disease who underwent transforaminal interbody fusion and PS fixation and received parathyroid hormone or bisphosphonate (BP) postoperatively.
Summary · context
They were divided into teriparatide group (daily injection of 20 μg of teriparatide for 6 months, 33 patients, 172 screws) and BP group (weekly oral administration of 35 mg of risedronate, 51 patients, 262 screws).
Summary · context
Both groups received calcium (500 mg/day) and cholecalciferol (1000 IU/day) together.
Report a problemFND-2972409303
04HumanObservational studyEfficacy outcome
After lumbar fusion in osteoporosis, teriparatide was linked to greater improvement in BMD T-score than risedronate.
In plain wordsAfter spine surgery, teriparatide was linked to greater improvement in bone density than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD T-score improvement
Study
n = 84
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
The teriparatide group showed a significantly higher degree of improvement of the bone mineral density (T-score) than that of BP group (p<0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this retrospective study was to examine the efficacy of teriparatide treatment started immediately after lumbar spinal surgery to prevent pedicle screw loosening in patients with osteoporosis.
Summary · context
We included 84 patients with osteoporosis and degenerative lumbar disease who underwent transforaminal interbody fusion and PS fixation and received parathyroid hormone or bisphosphonate (BP) postoperatively.
Summary · context
They were divided into teriparatide group (daily injection of 20 μg of teriparatide for 6 months, 33 patients, 172 screws) and BP group (weekly oral administration of 35 mg of risedronate, 51 patients, 262 screws).
Summary · context
Both groups received calcium (500 mg/day) and cholecalciferol (1000 IU/day) together.
Report a problemFND-2972409304
05HumanObservational studyEfficacy outcome
After lumbar fusion in osteoporosis, preoperative and postoperative VAS scores did not differ significantly between teriparatide and risedronate.
In plain wordsAfter spine surgery, pain scores did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVAS pain score
Study
n = 84
Comparator
Risedronate
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg daily · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference in the pre- and post-operative VAS and ODI between the groups.
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this retrospective study was to examine the efficacy of teriparatide treatment started immediately after lumbar spinal surgery to prevent pedicle screw loosening in patients with osteoporosis.
Summary · context
We included 84 patients with osteoporosis and degenerative lumbar disease who underwent transforaminal interbody fusion and PS fixation and received parathyroid hormone or bisphosphonate (BP) postoperatively.
Summary · context
They were divided into teriparatide group (daily injection of 20 μg of teriparatide for 6 months, 33 patients, 172 screws) and BP group (weekly oral administration of 35 mg of risedronate, 51 patients, 262 screws).
Summary · context
Both groups received calcium (500 mg/day) and cholecalciferol (1000 IU/day) together.
Report a problemFND-2972409305
06HumanObservational studyEfficacy outcome
After lumbar fusion in osteoporosis, preoperative and postoperative disability scores did not differ significantly between teriparatide and risedronate.
In plain wordsAfter spine surgery, disability scores did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOswestry disability index
Study
n = 84
Comparator
Risedronate
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg daily · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference in the pre- and post-operative VAS and ODI between the groups.
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this retrospective study was to examine the efficacy of teriparatide treatment started immediately after lumbar spinal surgery to prevent pedicle screw loosening in patients with osteoporosis.
Summary · context
We included 84 patients with osteoporosis and degenerative lumbar disease who underwent transforaminal interbody fusion and PS fixation and received parathyroid hormone or bisphosphonate (BP) postoperatively.
Summary · context
They were divided into teriparatide group (daily injection of 20 μg of teriparatide for 6 months, 33 patients, 172 screws) and BP group (weekly oral administration of 35 mg of risedronate, 51 patients, 262 screws).
Summary · context
Both groups received calcium (500 mg/day) and cholecalciferol (1000 IU/day) together.
Report a problemFND-2972409306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.